A new study published in the New England Journal Of Medicine claimed that it can tackle non-alcoholic steatohepatitis or NASH ...

Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...

Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Researchers at Peking University have discovered that a filamentous gut fungus, Fusarium foetens, can reverse metabolic ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Key outcomes of all-cause mortality and portal hypertension complications are improved with SGLT2inhibitors, new research ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial ...